Search

Displaying results 3851 - 3860 of 7502 in total
  1. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. … In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.

  2. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  3. Drug

    Clemastine

    go.drugbank.com/drugs/DB00283
    ApprovedInvestigational

    An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.

  4. Drug

    Soy isoflavones

    go.drugbank.com/drugs/DB14101
    Approved

    Mixtures: Cheon Shim Bo Yun
  5. Drug

    Zirconium chloride hydroxide

    go.drugbank.com/drugs/DB15479
    ApprovedWithdrawn

    Mixtures: Secret Sporty Clean Antiperspirant Roll-ON
  6. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets.

  7. Drug

    QS-21

    go.drugbank.com/drugs/DB05400
    Investigational

    As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics. … QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment

  8. Drug

    Melanoma antigen recognized by T-cells 1

    go.drugbank.com/drugs/DB15081
    Investigational

    Melanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

    Synonyms: Melanoma antigen recognized by T-cells 1
  9. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    This drug is developed by Ceregene and currently under phase I of clinical trial.

  10. Drug

    VE303

    go.drugbank.com/drugs/DB17794
    Investigational

    VE303 is under clinical development by Vedanta Biosciences.